Recursion Pharmaceuticals (NasdaqGS:RXRX) recently announced a $500 million Follow-on Equity Offering and revealed mixed earnings results for Q4 2024, which showed declining quarterly sales and ...

Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future ...

Q4 2024 Earnings Call Transcript February 28, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

The AES Corp.’s (AES) shares jumped 11.7% after the company reported fourth-quarter 2024 adjusted earnings per share of $0.54, surpassing the Zacks Consensus Estimate of $0.34. Shares of Recursion ...

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) had its target price dropped by Leerink Partners from $7.00 to ...

EST Cathie Wood’s ARK Investment buys 653K shares of Recursion Pharmaceuticals (RXRX) todayDiscover the Best Stocks and Maximize Your ...

TD Cowen analyst Brendan Smith maintained a Hold rating on Recursion Pharmaceuticals (RXRX – Research Report) today. The company’s shares ...

The clinical-stage TechBio company posted a loss of $0.53 per share for Q4, wider than the $0.41 loss analysts had forecast. Revenue came in at $4.55 million, significantly below the consensus ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Friday reported a loss of $178.9 million in its fourth quarter. On a per-share basis, the Salt Lake City-based ...

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological ...

ARK Invest purchased $9.3 million worth of Coinbase shares during a crypto market downturn while simultaneously selling $8.6 ...

Roche's drug portfolio shows promise, but mixed indicators reveal uncertainties. Check out the risks, opportunities, and ...